Loading...
Docoh

Kodiak Sciences (KOD)

Kodiak Sciences Inc. is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, Kodiak is focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Its ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, its bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and the company is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA.

Company profile

KOD stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 May 22
24 May 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 678.05M 678.05M 678.05M 678.05M 678.05M 678.05M
Cash burn (monthly) 19.93M 20.73M 31.92M 26.02M 14.39M 15.9M
Cash used (since last report) 35.38M 36.8M 56.67M 46.2M 25.54M 28.23M
Cash remaining 642.67M 641.25M 621.38M 631.85M 652.51M 649.82M
Runway (months of cash) 32.3 30.9 19.5 24.3 45.4 40.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
18 May 22 Baker Bros. Advisors Common Stock Buy Acquire P Yes No 5.9689 7,489 44.7K 15,142,074
18 May 22 Baker Bros. Advisors Common Stock Buy Acquire P Yes No 5.9689 912 5.44K 1,245,661
18 May 22 Baker Bros. Advisors Common Stock Buy Acquire P Yes No 5.9686 182,827 1.09M 15,134,585
18 May 22 Baker Bros. Advisors Common Stock Buy Acquire P Yes No 5.9686 22,266 132.9K 1,244,749
18 May 22 Baker Bros. Advisors Common Stock Buy Acquire P Yes No 5.9537 9,157 54.52K 14,951,758
18 May 22 Baker Bros. Advisors Common Stock Buy Acquire P Yes No 5.9537 1,115 6.64K 1,222,483
17 May 22 Baker Bros. Advisors Common Stock Buy Acquire P Yes No 5.9877 90,674 542.93K 14,942,601
17 May 22 Baker Bros. Advisors Common Stock Buy Acquire P Yes No 5.9877 11,043 66.12K 1,221,368
17 May 22 Baker Bros. Advisors Common Stock Buy Acquire P Yes No 5.9866 8,118 48.6K 14,851,927
17 May 22 Baker Bros. Advisors Common Stock Buy Acquire P Yes No 5.9866 989 5.92K 1,210,325
80.3% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 140 155 -9.7%
Opened positions 43 28 +53.6%
Closed positions 58 23 +152.2%
Increased positions 42 44 -4.5%
Reduced positions 40 55 -27.3%
13F shares Current Prev Q Change
Total value 326.41M 6.89B -95.3%
Total shares 41.74M 44.88M -7.0%
Total puts 326.9K 148.9K +119.5%
Total calls 627.2K 406.2K +54.4%
Total put/call ratio 0.5 0.4 +42.2%
Largest owners Shares Value Change
Baker Bros. Advisors 15.93M $122.99M +8.5%
BLK Blackrock 3.44M $26.53M +20.5%
Vanguard 2.36M $18.22M -20.6%
Wellington Management 1.46M $11.24M -73.3%
MS Morgan Stanley 1.36M $10.53M +440.0%
Millennium Management 1.06M $8.15M +8870.4%
ICONIQ Capital 1.02M $7.85M 0.0%
D. E. Shaw & Co. 997.82K $7.7M +31307.7%
Two Sigma Investments 989.58K $7.64M NEW
STT State Street 972.51K $7.51M -25.7%
Largest transactions Shares Bought/sold Change
TROW T. Rowe Price 684.15K -7.43M -91.6%
Wellington Management 1.46M -3.99M -73.3%
Baker Bros. Advisors 15.93M +1.25M +8.5%
MS Morgan Stanley 1.36M +1.11M +440.0%
Millennium Management 1.06M +1.04M +8870.4%
D. E. Shaw & Co. 997.82K +994.65K +31307.7%
Two Sigma Investments 989.58K +989.58K NEW
ArrowMark Colorado 0 -909.72K EXIT
Two Sigma Advisers 898.2K +865.1K +2613.6%
Marshall Wace 661.54K +661.54K NEW

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: absent, accessible, acuity, adware, alleviate, authentication, Avastin, BCVA, branch, Brazil, clarify, Colorado, destruction, differentiated, dual, email, encryption, endothelial, Extortion, extracellular, facilitate, factor, Feb, hardware, imputed, incremental, inhibitor, intracellular, invasion, length, mammalian, military, misuse, notification, NPDR, offline, online, pathophysiology, pause, persistent, phosphorylcholine, photographic, presence, PSO, reactivation, recombinant, retaliatory, retreatment, Russia, Russian, server, sham, Shanghai, surge, theft, threat, tight, Ukraine, unchanged, undertreatment, unlawful, Utah, Vabysmo, variant, Virginia, visual
Removed: accretion, adequacy, analyzing, anatomical, anesthesiologist, approving, ballot, beneficial, broaden, certification, certified, chart, codification, collection, Commerce, compromise, concurrent, context, contractually, conviction, correct, corruption, credit, DAZZLE, drying, Edition, enacting, encouraging, explicit, Exudation, fundamentally, genetic, globally, governance, headcount, immaterial, initially, insurer, interval, IPO, lawful, lesser, malfeasance, maturity, measure, measurement, notable, October, presentation, preventive, principle, ratably, realized, reclassified, reclassify, remediate, requisite, retina, robust, screening, Shield, topline, track, treasury, unrecognized, unvested, usability, valuation, vascular, Virtual, vision